Emergent Biosolutions soars 16% after FDA panel call - Breaking The News

Emergent Biosolutions soars 16% after FDA panel call

15 February

1 min read

EPA-EFE/SHAWN THEW

Emergent BioSolutions Inc.'s shares surged over 16% in extended trading on Wednesday after advisory committees for the United States Food and Drug Administration recommended selling its nasal spray Narcan over the counter.

The spray is a "treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression," according to the FDA, which is expected to announce its final formal decision on Narcan by March 29, 2023.

Emergent BioSolutions jumped 16.09% in after-hours trading.

opioid epidemic fda opioid opioid crisis emergent biosolutions

Related Stocks

Emergent Biosolut...

US FDA vaccine director resigns

an hour ago

The director of the United States Center for Biologics Evaluation and Research, Dr. Peter Marks (pictured), the head of the US Food and Drug Administration (FDA) responsible for verifying the safety and efficacy of vaccines, has resigned effective April 5, the Wall Street Journal reported.“It has become clear that truth and transparency are not desired by the [US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.], but rather he wishes subservient...

US Senate confirms Martin Makary to lead FDA

26 March

The United States Senate confirmed Dr. Martin Makary, a pancreatic surgeon, as commissioner of the Food and Drug Administration (FDA) in a 56-44 vote. The confirmation means that Makary, a surgeon at Johns Hopkins, will be in charge of regulation and oversight related to drugs, vaccines, food and other products. "Vaccines save lives, and I do believe that any child who dies of a vaccine-preventable illness is a tragedy in the modern era," Makary said...

Purdue Pharma owners to pay up to $7.4B in opioid settlement

23 January

New York Attorney General Letitia James announced on Thursday that the Sackler family members, who own the OxyContin maker Purdue Pharma, reached a settlement to pay up to $7.4 billion "for their instrumental role in creating the opioid crisis."According to the new settlement, the Purdue Pharma owners will contribute up to $7.4 billion over the span of 15 years, with a portion of the money going to the victims of the opioid crisis. The first payment of $1.5...

Trump's DEA administrator pick withdraws from consideration

3 December

Hillsborough County Sheriff Chad Chronister, United States President-elect Donald Trump's pick for administrator of the Drug Enforcement Agency (DEA), withdrew his name from consideration on Tuesday."To have been nominated by President-Elect @realDonaldTrump to serve as Administrator of the Drug Enforcement Administration is the honor of a lifetime," Chronister wrote on X, adding that the "gravity of this very important responsibility" made him...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.